Baird Downgrades Marinus Pharmaceuticals (MRNS) to Neutral, 'Phase 3 RAISE Study Doesn't Hit at Interim'
Tweet Send to a Friend
(Updated - April 16, 2024 4:40 AM EDT)
Baird analyst Brian Skorney downgraded Marinus Pharmaceuticals (NASDAQ: MRNS) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst Brian Skorney downgraded Marinus Pharmaceuticals (NASDAQ: MRNS) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
